The control group received a single daily oral dose of saline as a negative control for 4 weeks
What Is Zepbound (Tirzepatide)
Who Is an Ideal Candidate for GLOW GLOW is well suited for patients who: Heal slowly Have chronic soft-tissue injuries Plateau on single-peptide therapy Want durable structural repair Are undergoing regenerative procedures The Future of Peptide Therapy Is Systems-Based Single-peptide therapy reflects an outdated, reductionist model
People were randomly assigned to receive once-weekly subcutaneous injection of tirzepatide (5, 10, or 15 mg) or once-daily subcutaneous injection of titrated insulin degludec in the ratio of 1:1:1:1
This is relevant because hyperuricemia is common in people with obesity and metabolic syndrome, and elevated uric acid is associated with gout and cardiovascular risk
GIP, or glucose-dependent insulinotropic polypeptide, is a second hormone that works synergistically with GLP-1 to regulate appetite, blood sugar, and energy expenditure